Every Day Counts in the Race Against Cancer
Agilent is dedicated to pushing the boundaries of cancer research and diagnostics. Our innovative solutions and strategic partnerships are at the forefront of transforming cancer care, enabling us to deliver comprehensive multiomic insights and cutting-edge diagnostic tools that empower researchers and clinicians to make more informed decisions and ultimately improve patient care. Whether your early discovery research, clinical trials or diagnostic tools development, Agilent is there to support scientists with an integrated portfolio of solutions.
AACR 2025 Media Briefing Presentation
Supporting cancer research is a priority focus area for Agilent and our partners. Together we are committed to leveraging a portfolio of analytical instruments, solutions, and expertise to serve cancer-focused customers globally.
Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics
? Agilent Avida DNA Cancer Panels – Based on cutting-edge next-generation sequencing (NGS) target enrichment solutions that enable simultaneous DNA and methylation profiling from a single sample, the Avida product portfolio has expanded to include three new DNA panels*. Optimized based on the requirements of the European OncNGS Consortium, these catalog panels deliver ultra-sensitive and rapid detection of cancer-related genomic alterations from circulating cell-free DNA (cfDNA) in liquid biopsy samples. The streamlined DNA workflow generates sequencing-ready libraries in just five hours, enabling scientists to go from cfDNA samples to sequencing in a single day shift. These DNA panels can be paired with an Avida methylation panel to provide deep multiomic insights.
? Agilent SureSelect Cancer CGP Assay and Tagomics InterlaceTM Multiomics Assay – Agilent has partnered with Tagomics to gain early access to a novel, unbiased approach for epigenetic profiling. The combined workflow of the Tagomics Interlace Multiomics assay with the Agilent SureSelect Cancer CGP assay offers a comprehensive genomic profiling solution, delivering genome-wide epigenetic signatures alongside targeted DNA variant detection. This enables novel and informative multiomic insights into cancer biology to accelerate disease understanding and diagnosis.
? Agilent SureSelect Cancer Pan Heme Assay – Co-developed with the Roswell Park Comprehensive Cancer Center, this new assay interrogates DNA and RNA to provide comprehensive genomic profiling for hematologic malignancies. It is the first kitted assay with walkaway automation via the Agilent Magnis NGS Prep System, and an integrated, optimized secondary and tertiary data analysis software powered by QIAGEN Clinical Insight (QCI). This significantly improves laboratory productivity, efficiency, and turnaround time.
Agilent and Abcam Strategic Collaboration for (IHC) Companion Diagnostics (CDx) – This collaboration establishes a seamless paradigm for Agilent to develop a novel IHC CDx using Abcam's extensive portfolio of over 10,000 high-quality, extensively validated, and stringently manufactured recombinant monoclonal antibodies, RabMAbs?. The collaboration enables Agilent to expedite the development of custom assays for drug development and accelerates the use of assays in early clinical trials.
